These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10927799)

  • 21. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters.
    Minneboo A; Jasperse B; Barkhof F; Uitdehaag BM; Knol DL; de Groot V; Polman CH; Castelijns JA
    J Neurol Neurosurg Psychiatry; 2008 Aug; 79(8):917-23. PubMed ID: 18077480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological disturbances in the central nervous system linked to MRI findings in multiple sclerosis.
    Wang HY; Matsui M; Saida T
    J Neuroimmunol; 2002 Apr; 125(1-2):149-54. PubMed ID: 11960651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
    Killestein J; Den Drijver BF; Van der Graaff WL; Uitdehaag BM; Polman CH; Van Lier RA
    Mult Scler; 2001 Jun; 7(3):145-50. PubMed ID: 11475436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis.
    Sindern E; Patzold T; Ossege LM; Gisevius A; Malin JP
    J Neuroimmunol; 2002 Oct; 131(1-2):186-90. PubMed ID: 12458051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [CD40L expression on T CD4+ lymphocytes from peripheral blood in patients with relapsing-remitting and secondary progressive multiple sclerosis].
    Bilińska M; Frydecka I; Kosmaczewska A; Ciszak L; Koszewicz M; Pokryszko-Dragan A
    Pol Merkur Lekarski; 2006 Jan; 20(115):41-5. PubMed ID: 16617733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis.
    Jensen J; Krakauer M; Sellebjerg F
    Eur J Neurol; 2001 Jul; 8(4):321-8. PubMed ID: 11422428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.
    Zastepa E; Fitz-Gerald L; Hallett M; Antel J; Bar-Or A; Baranzini S; Lapierre Y; Haegert DG
    Neurology; 2014 Feb; 82(8):681-90. PubMed ID: 24453076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological and gadolinium-DTPA MRI evaluation of relapsing remitting multiple sclerosis.
    Capra R; Marcianó N; Cotti Cometti V; Vignolo LA; Bettinzioli M; Airó P; Cattaneo R; Gasparotti R; Moretti R
    Acta Neurol Scand; 1992 Oct; 86(4):342-5. PubMed ID: 1455979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
    Soldan SS; Alvarez Retuerto AI; Sicotte NL; Voskuhl RR
    J Immunol; 2003 Dec; 171(11):6267-74. PubMed ID: 14634144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulatory effects of Vitamin D in multiple sclerosis.
    Correale J; Ysrraelit MC; Gaitán MI
    Brain; 2009 May; 132(Pt 5):1146-60. PubMed ID: 19321461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS.
    Balashov KE; Comabella M; Ohashi T; Khoury SJ; Weiner HL
    Neurology; 2000 Jul; 55(2):192-8. PubMed ID: 10908889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis.
    Khoury SJ; Orav EJ; Guttmann CR; Kikinis R; Jolesz FA; Weiner HL
    Neurology; 1999 Sep; 53(4):758-64. PubMed ID: 10489037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymic output and peripheral T lymphocyte subsets in relapsing--remitting multiple sclerosis patients treated or not by IFN-beta.
    Puissant-Lubrano B; Viala F; Winterton P; Abbal M; Clanet M; Blancher A
    J Neuroimmunol; 2008 Jan; 193(1-2):188-94. PubMed ID: 18068811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability.
    Prat A; Biernacki K; Saroli T; Orav JE; Guttmann CR; Weiner HL; Khoury SJ; Antel JP
    Arch Neurol; 2005 May; 62(5):795-800. PubMed ID: 15883268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.
    Whitaker JN; Wolinsky JS; Narayana PA; Bartolucci AA; Noseworthy JH; Lublin FD; Linde A; Gjörstrup P; Sullivan HC;
    Arch Neurol; 2001 Jan; 58(1):49-54. PubMed ID: 11176936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL; Wynn DR; Alam MS; Valdes J
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.